Loren Data's SAM Daily™

FBO DAILY ISSUE OF JANUARY 25, 2004 FBO #0789
SOLICITATION NOTICE

68 -- Synthesis of 2'-Alkoxy, 3'-deoxyphosphatidylinsolitol ether lipid0 analogues

Notice Date

1/23/2004
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-40030-NG
 

Response Due

2/9/2004
 

Archive Date

2/24/2004
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
 

E-Mail Address

holdcram@exchange.nih.gov, rs442i@nih.gov
 

Description

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Cancer Therapeutics Branch (CTB) plans to procure supplies and services for Synthesis of 2'-Alkoxy, 3'-deoxyphosphatidylinsolito ether lipid analogues" from Acenta Discovery, Inc, 9030 South Rita Road, Tucson, Arizona, 85747. The supplies and services herein are being procured in accordance with the simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification System Code is 325411 and the business size standard is 750 employees. The Signal Transduction Section of the NCI, studies signaling pathways involved in tumors. The goals of this section are to identify clinically relevant kinases whose modification may alter tumor formation and/or growth, and to develop approaches to inhibit theses identified kinases. Akt (or, Protein kinase B (PKB)) is a well -characterized serine/theonine kinase that promotes cellular survival. Akt can be activated in response to growth stimuli as well as stressful stimuli. Activation requires phosphorylation of 2 amino acids, one in the activation domain and one in the C-terminal hydrophobic motif. Phosphorylation of the site in the activation domain is dependent on the products of an upstream kinase, phosphatidylinositol 3-kinase (PI3-K), phosphatidylinositol 3, 4 biphosphate (PIP2) and phosphatidylinositol 3, 4, 5 triphosphate (PIP3). PIP2 and PIP 3 bind to pleckstrin homology (PH) domain of Akt, which result in translocation of AKT to the plasma membrane, where the two phosphorylation events subsequently occur. NCI, CTB has collaborated with Alan Kozikowski at Georgetown University, also with University of Illinois at Chicago and Scientific advisor to Acenta Discovery, who has molecularly modeled the interaction of PIP2 and PIP3 with the PH domain of Akt, and has synthesized phosphatidylinositol (PI) ether lipid analogues that were designed to inhibit the binding of PIP2 and PIP3 to the PH domain of Akt, thereby inhibiting Akt activity. Increased synthesis will allow further study into the biologic activity of these compounds and allow the Developmental Therapeutics Program to assess the suitability of these compounds for further development as possible drugs. The NCI and Georgetown University are co-Inventors of these compounds, and they can only be made efficiently by the team at Acenta Discovery with the consultation of Dr. Kozikowski, developer of these compounds. Period of Performance: Upon award through six (6) months; FAR Clause 52.217-8 Option to Extend services (November 1999) applies. Requirement: The biologic studies and animal studies will require synthesis of approximately 100 mg of each effective compound (SH5, 6, 23, 24 and 25) as well as 100 mg of an ether lipid analogue that lacks an inositol ring and, therefore, serves as a negative control. Additionally, 10 mg amounts of each of the inositol head groups will be required. Acenta Discovery, Inc. is the only source known to the NCI that can provide the expertise to synthesize the compounds needed to continue the existing experiment in progress. Dr. Kozikowski is a Professor and Head of the Department of Medicinal Chemotherapy and Parmacognosy at the University of Illinois at Chicago and the founder of Acenta Discovery. He has published extensively on the synthesis of compounds designed to inhibit various molecular targets. Importantly, he was the first to discover and synthesized 3'deoxyphosphatidylinositol ether lipid analogues that serve as precursors for the 2'-alkoxy-, 3'-deoxyphosphatidylinositol ether lipid analogues. His compound synthesis is innovative, elegant, consistent and reliable. The compounds themselves are unique and have not been described in the literature. These compounds could eventually be used to treat cancer or other diseased characterized by Akt activation. This is not a request for competitive quotation. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 1:00 PM EST, February 9, 2004. If you have any questions they must be submitted in writing to Malinda Holdcraft, Purchasing Agent, at holdcram@exchange.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Solicitation number must be cited on all correspondence, NCI-40030-NG.
 

Place of Performance

Address: NCI

Zip Code: 20892

Country: USA
 

Record

SN00508883-W 20040125/040123211853 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |